Janssen-Cilag Ltd. clinical trials

A country office of Johnson & Johnson

The registry lists 98 studies whose lead sponsor is Janssen-Cilag Ltd.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 1, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 98. List all 98 → · All Johnson & Johnson studies →

• A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian SettingNot yet recruitingNCT07851207

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative ColitisNot yet recruitingNCT07848737

  Sponsor listed in the registry: Janssen-Cilag, S.A.

• A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis ParticipantsRecruitingNCT07532226

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)RecruitingNCT07242248

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical TrialsRecruitingNCT06285318

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease PatientsActive, not recruitingNCT06408935Phase 3

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's DiseaseActive, not recruitingNCT05347095Phase 3

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or EnzalutamideCompletedNCT05901649

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe PsoriasisTerminatedNCT07449234

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Real-world Study in Participants With Smoldering Multiple MyelomaCompletedNCT06472778

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer PainCompletedNCT00771199Phase 4

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray TreatmentCompletedNCT04829318Phase 4

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or SelexipagCompletedNCT04567602

  Sponsor listed in the registry: Janssen-Cilag S.p.A.

• A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric EmergencyWithdrawnNCT04829669

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT03782376Phase 3

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With UstekinumabCompletedNCT03107793Phase 3

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Treatment Resistant Depression in America LatinaCompletedNCT03207282

  Sponsor listed in the registry: Janssen-Cilag, S.A.

• A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in ItalyCompletedNCT04463108

  Sponsor listed in the registry: Janssen-Cilag S.p.A.

• A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month FormulationCompletedNCT02713282Phase 3

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study to Evaluate the Impact of Care4Today® IBD, a Smart System to Facilitate the Management of Crohn's Disease by Patients and Health Care ProvidersTerminatedNCT04232228

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Treatment-Resistant Depression Cohort in EuropeCompletedNCT03373253

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody TreatmentCompletedNCT04035226

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque PsoriasisTerminatedNCT05125679Phase 4

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's DiseaseCompletedNCT03495973

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Study to Describe the Actual Situation of Hepatitis C Treatment in BrazilCompletedNCT02773394

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide FumarateCompletedNCT03577470

  Sponsor listed in the registry: Janssen-Cilag S.p.A.

• A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) PsoriasisCompletedNCT04439526

  Sponsor listed in the registry: Janssen-Cilag S.p.A.

• An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment AlternativesCompletedNCT04476446Phase 3

  Sponsor listed in the registry: Janssen-Cilag, S.A.

• A Registry Study of Participants With Multiple Myeloma in Latin AmericaCompletedNCT03955900

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical PracticeCompletedNCT03425591

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World SettingCompletedNCT03720561

  Sponsor listed in the registry: Janssen-Cilag S.p.A.

• A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular PsoriasisCompletedNCT03998683Phase 3

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDsCompletedNCT03131661

  Sponsor listed in the registry: Janssen-Cilag S.p.A.

• Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical TrialCompletedNCT01177059Phase 2

  Sponsor listed in the registry: Janssen-Cilag Pty Ltd

• Evaluation of the Functional Remission Occurrence and Predictive Factors in SchizophreniaCompletedNCT02874560

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)CompletedNCT02926456

  Sponsor listed in the registry: Janssen-Cilag S.p.A.

• Study to Investigate Effects of Repeated Administration of Itraconazole on Pharmacokinetics of JNJ-42847922 in Healthy Male ParticipantsCompletedNCT02455856Phase 1

  Sponsor listed in the registry: Janssen Cilag N.V./S.A.

• Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male ParticipantsCompletedNCT02448004Phase 1

  Sponsor listed in the registry: Janssen Cilag N.V./S.A.

• Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to GolimumabTerminatedNCT02414984

  Sponsor listed in the registry: Janssen-Cilag, S.A.

• An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV InfectionCompletedNCT02597270

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 InfectionCompletedNCT00074997Phase 2

  Sponsor listed in the registry: Janssen-Cilag Pty Ltd

• A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With AntipsychoticsCompletedNCT02712463

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 PatientsCompletedNCT01702090Phase 4

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)CompletedNCT01362426

  Sponsor listed in the registry: Janssen-Cilag Pty Ltd

• IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute AgitationCompletedNCT01050478Phase 4

  Sponsor listed in the registry: Janssen Cilag N.V./S.A.

• ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.CompletedNCT00440479

  Sponsor listed in the registry: Janssen-Cilag B.V.

• Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican PopulationCompletedNCT02385058Phase 4

  Sponsor listed in the registry: Janssen-Cilag Ltd.

• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male ParticipantsCompletedNCT01964872Phase 1

  Sponsor listed in the registry: Janssen Cilag N.V./S.A.

• An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month PeriodCompletedNCT00299676

  Sponsor listed in the registry: Janssen-Cilag Pty Ltd